Heparin Market Research Report Information By Product (Unfractionated Heparin (UFH), Low Molecular Weight Heparin (LMWH)), By Source (Bovine, Porcine), By Application (Deep Vein Thrombosis & Pulmonary Embolism, Atrial Fibrillation, Heart Attacks, Stroke, Others), By Route of Administration (Intravenous Infusion, Subcutaneous Injection), By End user (Hospitals & ASCS, Clinics, Others), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032

Global Heparin Market Overview

Heparin Market Sizewas valued at USD 9.6 Billion in 2023. The Heparin market industry is projected to grow from USD 9.89 Billion in 2024 to USD 12.2 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 3.00% during the forecast period (2024 - 2032). The rising geriatric population and increasing investment in healthcare infrastructure are the key market driversboosting the expansion of the market.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Heparin Market Trends

• 
  

  Increasing Investment in Healthcare Infrastructure is Driving the Market Growth

  
  

Market CAGR for Heparin is being driven by the increasing investment inhealthcare infrastructure. During surgical procedures, heparin, an injectable anticoagulant, is used to prevent blood from clotting in arteries and veins. Anyway, it is moreover used to treat blood coagulating wrecks. It is also used to treat and diagnose pulmonary embolism, venous thromboembolism, and arterial thromboembolism. Heparin is also referred to as unfractionated heparin. Heparin comes from the tissues of butchered meat and is an inferred product of animals.

Additionally, the instances of constant blood infections are developing dramatically and will probably drive the overall antiplatelet drugs market. Expansion in the commonness of persistent illnesses, such as cardiovascular sicknesses, is attributable to driving the market. The rising occurrences of cardiovascular infections are a central point driving the ant platelet drugs market's development rate. In both created and created economies, cardiovascular sicknesses are the main source of death. Rising drives by open and confidential associations to spread mindfulness bunch parasitic diseases will extend the worldwide heparin market. Also, high discretionary cash flow and the stationary way of life of individuals will bring about the development of the worldwide heparin market. Alongside this, the rising geriatric populace and flood in thrombotic occasions will upgrade the market's development rate.

Due to their higher risk of heart disease, the growing geriatric population is likely to increase demand for heparin. It is guessed that the number of individuals north of 65 will twofold before very long. The prevalence of a wide range of long-term conditions, including cardiovascular diseases, among the elderly may raise the demand for herparin. The rising demand for transfusions of whole blood and blood components is driving up demand for heparin. Many spots generally can't satisfy their need for blood. Numerous efforts are being made to increase the number of blood donors.

For instance, the World Health Organization (WHO) appraises that Atrial fibrillation influences 37,574 million individuals around the world, or 0.51 percent of the populace, and its predominance has expanded by 33% in the past twenty years. Additionally, the focus noted that countries with high socioeconomic profiles have the highest weight, whereas countries with low socioeconomic profiles have experienced the most recent growth. Thus,result in driving the Heparin market revenue.

Heparin market Segment Insights

Heparin Product Insights

The Heparin Market segmentation, based on Product, includes Unfractionated Heparin (UFH) and Low Molecular Weight Heparin (LMWH). In 2023, the Low Molecular Weight Heparin (LMWH) segment dominated the market. This is due to the product's high rate of adoption in developed markets and superior safety profiles to those of other products. Fragmin (Dalleparin sodium) is one important LMWH product.

Heparin Source Insights

The Heparin Market segmentation, based on Source, includes Bovine and Porcine. In 2023, The Porcine category generated the most income. Porcine-based items are the main allowed rendition from a creature-based source. The development of the fragment is owing to the rising pace of the conclusion of cardiovascular sicknesses in arising and created nations. The absence of accessibility of other creature-based choices as an anticoagulant is set to expand the reception rate.

Heparin Application Insights

The Heparin Market segmentation, based on Application, includes Deep Vein Thrombosis & Pulmonary Embolism, Atrial Fibrillation, Heart Attacks, Stroke, and Others. In 2023, the heart attacks segment dominated the market because of the huge extent of the general population experiencing this illness, and one of the main intercessions is the organization of injectable anticoagulants.

Heparin Route of Administration Insights

The Heparin Market segmentation,based on Route of Administration, includes Intravenous Infusion and Subcutaneous Injection. In 2023, the Subcutaneous Injection generated the most income. This is ascribed to the way that LMWH is normally managed subcutaneously. When compared to other methods of administration, technological advancements and the sophistication of subcutaneous injections account for the segment's expansion.

Heparin End user Insights

The Heparin Market segmentation,based on End user, includes Hospitals & ASCS, Clinics, and Others. In 2023, the Hospitals & ASCS generated the most income. This is because people are more reliant on medical professionals to prescribe these products and give them the right way, especially through intravenous infusion.

Figure1: Heparin Market, by End user, 2023 & 2032 (USD Billion)

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Heparin Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American Heparin market area will dominate this market, owing to a rising frequency of cardiovascular sicknesses, venous thromboembolism, and other constant circumstances. In addition, the growing number of established health clubs and fitness facilities will boost market growth in this region.

Further, the major countries studiedin the market reportare the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: HEPARIN MARKET SHARE BY REGION 2023 (USD Billion)

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Europe Heparin market has the second-largest portion of the market due to the rising number of cardiovascular cases and government initiatives. Further, the German Heparin market had the biggest market share, and the UK Heparin market was the European market with the quickest rate of growth.

The Asia-Pacific Heparin market is anticipated to expand between 2024 and 2032 at the quickest CAGR. This is due to the expansion of Heparin products, which have become more appealing to healthcare providers and patients as a result of improvements in pharmaceutical technology. Moreover, China’s Heparin market had the biggest market share, and the Indian Heparin market was the Asia-Pacific region's fastest-growing market.

Heparin Key Market Players & Competitive Insights

Leading market players are putting a lot of money into research and development to expand their product lines, which will drive the market for Heparin to expand even further. Additionally, market players are engaging in a range of calculated initiatives to increase their worldwide presence, with important market developments involving the introduction of new products, contracts, M&A transactions, increased investment, and cooperation with other enterprises. To grow and endure in an increasingly cutthroat and dynamic market, the Heparin industry must provide reasonably priced goods.

Manufacturing locally is one of the primary business techniques used by manufacturers to cut operational costs in the global Heparin industry to help customers and expand the market segment. In recent years, the Heparin industry has provided some of the biggest benefits to medicine. Major players in the Heparin market, including Opocrin S.p.A. (Italy), Baxter (U.S.), Pfizer Inc. (U.S.), Bioiberica S.A.U. (Spain), Fresenius SE & Co. KGaA (Germany), Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (China), and B. Braun SE (Germany)are engaging in research and development activities in an effort to boost market demand.

Baxter is a worldwide association with tasks in excess of 100 countries and a central command in Deerfield, Illinois, where it was established in 1931.The company focuses on biosurgery, renal care (including dialysis), and medicine delivery, making it a major player in the medical services industry. Baxter manufactures a wide range of medical devices that are utilized in healthcare facilities and hospitals. This includes anesthetic products, IV solutions, and infusion pumps. Particularly in the field of dialysis, Baxter is a major supplier of renal consideration products. They make hemodialysis machines, peritoneal dialysis game plans, and other related things for patients with kidney contamination. Private equity firms Advent International and Warburg Pincus will acquire Baxter's biopharma solutions business. InMay 2023, for $4.25 billion in cash, this business will provide drugmakers with support in the form of injectable delivery systems and services, including regulatory resources, assistance with drug formulation and development, and packaging capabilities.

The corporate headquarters of Pfizer Inc., an American multinational pharmaceutical and Biotechnology Company, are located at The Spiral in Manhattan, New York City. Two German money managers named Charles Pfizer established the organization in New York in 1849. Two cousins who had immigrated to the US from Ludwigsburg, Germany, CharlesPfizer and Charles F. Erhart framed Pfizer as "Charles Pfizer and Company" in 1849. The antiparasitic santonin was one of the chemicals produced by the business, which had its headquarters on Bartlett Street in Williamsburgh, New York. Despite the fact that Pfizer's extension during the 1880s was, for the most part, because of the advancement of citrus extract, this was a moment achievement. In July 2019, Therachon's recombinant human fibroblast development factor receptor 3 compound, which is expected to deal with conditions like achondroplasia, was obtained by the organization for up to $810 million, extending its uncommon illness portfolio. Pfizer expanded its oncology pipeline by securing Exhibit Biopharma for $10.6 billion in July.

Key Companies in the Heparin market include

• Opocrin S.p.A. (Italy)


• Baxter (U.S.)


• Pfizer Inc. (U.S.)


• Bioiberica S.A.U. (Spain)


• Fresenius SE & Co. KGaA (Germany)


• Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (China)


• Braun SE (Germany)


• Reddy's Laboratories Ltd. (India)


• LEO Pharma A/S (Denmark)


• Aspen Holdings (South Africa)


• Sanofi (France)

HeparinIndustry Developments

April 2020: The acquisition of all of LaboratoriDerivatiOrganiciSpA (LDO) stocks by Opocrin S.p.A. was made public by Cerus Advisors DMCC (CERUS), a boutique family office management firm. The item arrangement of LDO comprises heparin alongside a progression of other specific natural APIs.

February 2020: The United States, Meitheal Pharmaceuticals announced FDA endorsement of extra assembling limit and future office extension plans for the creation of Heparin Sodium Infusion, USP

April 2019: B Braun Clinical Inc. declared the send-off of another Heparin Sodium infusion in the U.S. This is the principal heparin pre-filled needle with an appended security needle for subcutaneous or intravenous use.

Heparin Market Segmentation

Heparin Product Outlook

• Unfractionated Heparin (UFH)


• Low Molecular Weight Heparin (LMWH)

Heparin Source Outlook

• Bovine


• Porcine

Heparin Application Outlook

• Deep Vein Thrombosis & Pulmonary Embolism


• Atrial Fibrillation


• Heart Attacks


• Stroke


• Others

Heparin Route of Administration Outlook

• Intravenous Infusion


• Subcutaneous Injection

Heparin End user Outlook

• Hospitals & ASCS


• Clinics


• Others

Heparin Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America